Blood coagulation and fibrinolysis in patients with Cushing's syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels

被引:86
作者
Erem, C. [1 ]
Nuhoglu, I. [1 ]
Yilmaz, M. [2 ]
Kocak, M. [1 ]
Demirel, A. [1 ]
Ucuncu, O. [1 ]
Ersoz, H. Onder [1 ]
机构
[1] Karadeniz Tech Univ, Fac Med, Dept Internal Med, Div Endocrinol & Metab, TR-61080 Trabzon, Turkey
[2] Div Hematol, Trabzon, Turkey
关键词
Cushing's syndrome; Hemostasis; thrombin-activatable fibrinolysis inhibitor; tissue factor pathway inhibitor; RECURRENT VENOUS THROMBOEMBOLISM; HYPERCOAGULABLE STATE; ISCHEMIC-STROKE; CARDIOVASCULAR RISK; DISEASE; COMPLICATIONS; ANTITHROMBIN; MARKERS; EVENTS; PHASE;
D O I
10.1007/BF03345709
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Background and objectives: Cushing's syndrome (CS) is associated with an increased cardiovascular mortality and morbidity. Chronic endogenous and exogenous hypercortisolism frequently induce a hypercoagulable and thrombotic condition. Little is known about hemostatic features of patients with CS. To our knowledge, plasma tissue factor pathway inhibitor (TFPI) and thrombin-activatable fibrinolysis inhibitor (TAFI) levels in these patients have not been investigated. Therefore, the main purpose of this study was to evaluate the markers of endogenous coagulation/fibrinolysis, including TFPI and TAR, and to investigate the relationships between cortisol and these hemostatic parameters and serum lipid profile in patients with CS. Design and methods: Twenty-four patients with CS and 24 age-matched healthy controls were included in the study. Prothrombin time (PT), activated partial thromboplastin time (aPTT) fibrinogen, factors V, VII, VIII, IX, and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA), tissue plasminogen activator inhibitor-1 (PAI-1), TFPI and TAR, as well as common lipid variables, were measured. The relationships between serum cortisol and these hemostatic parameters were examined. Results: Compared with the control subjects, platelet count, PT, fibrinogen, AT-III and PAI-1 were significantly increased in patients with CS (p<0.05, p<0.0001, p<0.01, p<0.05, and p<0.0001, respectively), whereas aPTT and TFPI levels were significantly decreased (p<0.0001 and p<0.01, respectively). Plasma TAFI Ag levels did not significantly change in patients with CS compared with the controls. In patients with CS, we showed a negative correlation between serum cortisol: 08:00 h and aPTT (r:-0.469, p<0.05). Serum cortisol: 24:00 h was positively correlated with PAI-1 Ag levels (r: 0.479, p<0.05). Interpretation and conclusions: In conclusion, we found some important differences in the hemostatic parameters between the patients with CS and healthy controls. Increased platelet count, fibrinogen, PAI-1, and decreased TFPI levels in these patients represent a potential hypercoagulable and hypofibrinolytic state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess of mortality due to cardiovascular disease seen in patients with CS. (J. Endocrinol. Invest. 32: 169-174, 2009) (C) 2009, Editrice Kurtis
引用
收藏
页码:169 / 174
页数:6
相关论文
共 46 条
[1]
ABUMIYA T, 1995, THROMB HAEMOSTASIS, V74, P1050
[2]
Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma [J].
Ambrosi, B ;
Sartorio, A ;
Pizzocaro, A ;
Passini, E ;
Bottasso, B ;
Federici, A .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2000, 108 (04) :294-298
[3]
Diagnosis and complications of Cushing's syndrome: A consensus statement [J].
Arnaldi, G ;
Angeli, A ;
Atkinson, AB ;
Bertagna, X ;
Cavagnini, F ;
Chrousos, GP ;
Fava, GA ;
Findling, JW ;
Gaillard, RC ;
Grossman, AB ;
Kola, B ;
Lacroix, A ;
Mancini, T ;
Mantero, F ;
Newell-Price, J ;
Nieman, LK ;
Sonino, N ;
Vance, ML ;
Giustina, A ;
Boscaro, M .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (12) :5593-5602
[4]
PURIFICATION AND CHARACTERIZATION OF TAFI, A THROMBIN-ACTIVABLE FIBRINOLYSIS INHIBITOR [J].
BAJZAR, L ;
MANUEL, R ;
NESHEIM, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (24) :14477-14484
[5]
Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome [J].
Baykan, Merih ;
Erem, Cihangir ;
Gedikli, Oemer ;
Hacihasanoglu, Arif ;
Erdogan, Turan ;
Kocak, Mustafa ;
Durmus, Ismet ;
Korkmaz, Levent ;
Celik, Suekrue .
ENDOCRINE, 2007, 31 (03) :300-304
[6]
Bayston TA, 1997, THROMB HAEMOSTASIS, V78, P339
[7]
Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome [J].
Boscaro, M ;
Sonino, N ;
Scarda, A ;
Barzon, L ;
Fallo, F ;
Sartori, MT ;
Patrassi, GM ;
Girolami, A .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) :3662-3666
[8]
BROZE GJ, 1992, SEMIN HEMATOL, V29, P159
[9]
Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure [J].
Colao, A ;
Pivonello, R ;
Spiezia, S ;
Faggiano, A ;
Ferone, D ;
Filippella, M ;
Marzullo, P ;
Cerbone, G ;
Siciliani, M ;
Lombardi, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (08) :2664-2672
[10]
Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease [J].
Dagenais, GR ;
Yi, QL ;
Mann, JFE ;
Bosch, J ;
Pogue, J ;
Yusuf, S .
AMERICAN HEART JOURNAL, 2005, 149 (01) :54-60